Business
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL)...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Pricing of Public Offering of Common SharesOakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (\"Cardiol\" or the \"Company\"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the \"Offering\") of 8,437,500 Class A common shares of the Company (the \"Common Shares\") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.The Offering is expected to close on or about October 10, 2024 (the \"Closing Date\"), subject to the satisfaction of customary closing conditions, including the listing of the Common Shares to be issued under the Offering on the Toronto Stock Exchange (the \"TSX\") and the Nasdaq Capital Market (the \"Nasdaq\"), receipt of any required approvals of the TSX and Nasdaq, and the entering into of an underwriting agreement between the Company and the underwriter.The Offering is being made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commissions (the \"SEC\") on July 16, 2024 (the \"Registration Statement\"), and the Company's existing Canadian short form base shelf prospectus (the \"Base Prospectus\") dated July 12, 2024. A preliminary prospectus supplement relating to the Offering has been filed with the securities commission in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States, and a final prospectus supplement relating to the Offering (the \"Supplement\") will be filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospect...